Buy The Dip: 2 Top Undervalued Stocks Averaging 394% Forward EPS Growth
Ironwood Pharmaceuticals Inc IRWD
$4.23
▲ +13.40%
(+$0.50)
⬆️ Above Yest. High
📅 Earnings This Week
Open
$3.93
Prev Close
$3.73
Day Range
$3.87 – $4.28
52W Range
$0.72 – $5.78
Market Cap
$696.31M
P/E (TTM)
6.81
Beta
0.21
EPS (TTM)
$0.58
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2010-02-03 |
| Shares Out. | 164,610,000 |
| Website | ironwoodpharma.com/ ↗ |
| Phone | 13026587581 |
| Employees | 100 |
| Revenue | $106.5M |
| Gross Profit | $106.5M |
| Net Income | $40.8M |
| Free Cash Flow | $112.2M |
| Total Assets | $434.6M |
| Total Liabilities | $651.7M |
| Equity | -$217.1M |
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Ironwood Pharmaceuticals Inc is a publicly traded company under the ticker symbol IRWD on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-07-01)